AssayIndex

WXT-2508-G4723

Semaglutide · 3 mg declared · WuXi TIDES (WuXi AppTec Testing Division) · manufactured 25 Aug 2025

CHARACTERISED
Lot code
WXT-2508-G4723
Supplier
WXT — WuXi TIDES (WuXi AppTec Testing Division)
Compound
Semaglutide
Compound class
Incretin analogues and co-agonists
Declared label claim
3mg
Manufacture date
25 Aug 2025
Index quarter
2025-Q3
Independent assays
17
Laboratories involved
PeptideMeter, Nordanalyt, VendorInvestigate, Medutest, Janoshik
Provenance mix
Buyer-sourced ×11 · Supplier-supplied ×4 · Laboratory-retained ×2
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 17
Median purity 98.25% n=17
Spread (max − min) 1.20pp n=17
Standard deviation 0.324pp n=17
96.597.197.798.398.999.6100.2This lot (WXT-2508-G4723)This lot (WXT-2508-G4723): Q1 98.15, median 98.25, Q3 98.56, n=17n=17All SemaglutideAll Semaglutide: Q1 98.39, median 98.91, Q3 99.31, n=862outlier 96.72outlier 96.84outlier 96.92outlier 96.96outlier 96.97outlier 96.97n=862 Purity (% area)
Figure 1. This lot's independent purity results against the whole Semaglutide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 97.0 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 17

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-021132WXT-2508-G4723PeptideMeter2025-Q398.152.54Buyer-sourced0PASS
AX-2025-021133WXT-2508-G4723Nordanalyt2025-Q398.053.4098.6Buyer-sourced0PASS
AX-2025-021134WXT-2508-G4723VendorInvestigate2025-Q398.562.56102.6Laboratory-retained0PASS
AX-2025-021135WXT-2508-G4723PeptideMeter2025-Q398.373.1688.6Buyer-sourced1MARGINAL
AX-2025-021136WXT-2508-G4723Medutest2025-Q398.482.77Buyer-sourced0PASS
AX-2025-021137WXT-2508-G4723Medutest2025-Q397.732.89Buyer-sourced0PASS
AX-2025-021138WXT-2508-G4723Janoshik2025-Q398.562.75Laboratory-retained0PASS
AX-2025-021139WXT-2508-G4723Nordanalyt2025-Q398.162.89Buyer-sourced0PASS
AX-2025-021140WXT-2508-G4723Janoshik2025-Q398.633.26Supplier-supplied0PASS
AX-2025-021141WXT-2508-G4723Janoshik2025-Q398.683.15Supplier-supplied0PASS
AX-2025-021142WXT-2508-G4723Nordanalyt2025-Q398.562.7090.2Supplier-supplied0PASS
AX-2025-021143WXT-2508-G4723PeptideMeter2025-Q398.252.9794.2Buyer-sourced0PASS
AX-2025-021144WXT-2508-G4723Janoshik2025-Q398.192.8598.9Buyer-sourced0PASS
AX-2025-021145WXT-2508-G4723Janoshik2025-Q397.823.4291.7Buyer-sourced0PASS
AX-2025-021146WXT-2508-G4723Janoshik2025-Q398.932.87100.5Supplier-supplied0PASS
AX-2025-021147WXT-2508-G4723PeptideMeter2025-Q397.973.00Buyer-sourced0PASS
AX-2025-021148WXT-2508-G4723Janoshik2025-Q398.212.54Buyer-sourced1MARGINAL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
PeptideMeter498.15, 98.37, 98.25, 97.9798.2028min-0.0598.25
Nordanalyt398.05, 98.16, 98.5698.1635min+0.0298.14
VendorInvestigate198.5698.5632min-0.1198.67
Medutest298.48, 97.7398.1125min+0.0898.03
Janoshik798.56, 98.63, 98.68, 98.19, 97.82, 98.93, 98.2198.5630min+0.0098.56

This lot contributes 10 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)98.1298.15divergence -0.13 pp vs batch median
Total impurities (% area)not stated1.85
Largest single impurity (% area)not stated1.20
Water (%)2.12.54
Counter-ion (%)4.37.76
Peptide content (%w/w)93.0not determined
Endotoxin (EU/mg)0.81not determined
Method stated on certificateNOno method section — the result cannot be reconciled against any other
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
C18 diacid mono-ester17 / 170.740.05–1.20
[D-Aib8]-diastereomer17 / 170.270.20–0.58
des-AEEA semaglutide (−145 Da)17 / 170.090.04–0.35
des-His1 truncate (−137 Da)17 / 170.050.03–1.17
Met(O) sulfoxide (+16 Da)16 / 170.030.02–0.04
deamidated (Asn→Asp, +1 Da)9 / 170.170.05–0.22
semaglutide dimer8 / 170.040.03–0.05
Section 7

What this rollup does not establish